SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/0480F2FF5843B781E027AF91F281C3C1CDEBFDF2B8ACBA3F8026637A055984B54159B392BFDD47B208905FC62092AF83>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/0480F2FF5843B781E027AF91F281C3C1CDEBFDF2B8ACBA3F8026637A055984B54159B392BFDD47B208905FC62092AF83
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/0480F2FF5843B781E027AF91F281C3C1CDEBFDF2B8ACBA3F8026637A055984B54159B392BFDD47B208905FC62092AF83
http://www.w3.org/2000/01/rdf-schema#comment
"Increased CCL2 expression is associated with resistance to vemurafenib in melanoma."
xsd:string
http://purl.uniprot.org/uniprot/#_4207D3B9171E0F773FBE311D8FD4F38F465D046A9A95AFC1CBE2F97959197E2303B048E8B79E09CFBBBDBC340CD9C3C3
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/0480F2FF5843B781E027AF91F281C3C1CDEBFDF2B8ACBA3F8026637A055984B54159B392BFDD47B208905FC62092AF83
http://purl.uniprot.org/uniprot/J3KRT7
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/0480F2FF5843B781E027AF91F281C3C1CDEBFDF2B8ACBA3F8026637A055984B54159B392BFDD47B208905FC62092AF83
http://purl.uniprot.org/uniprot/#_J3KRT7-mappedCitation-26684239
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/0480F2FF5843B781E027AF91F281C3C1CDEBFDF2B8ACBA3F8026637A055984B54159B392BFDD47B208905FC62092AF83